[{"id":"65a39e57-0fe4-43a3-8e14-9aae8f76d3a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT06124157","created_at":"2023-11-09T16:12:44.229Z","updated_at":"2025-02-25T14:42:30.057Z","phase":"Phase 3","brief_title":"A Study Comparing the Combination of Dasatinib and Chemotherapy Treatment With or Without Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or Philadelphia Chromosome-Like (Ph-Like) ABL-Class B-Cell Acute Lymphoblastic Leukemia (B-ALL)","source_id_and_acronym":"NCT06124157","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • KIT • PDGFRA • CD19 • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Starasid (cytarabine ocfosfate)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 680","initiation":"Initiation: 05/29/2025","start_date":" 05/29/2025","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2025-02-14"},{"id":"4448c756-db79-4484-aae6-303e6174097b","acronym":"AALL1631","url":"https://clinicaltrials.gov/study/NCT03007147","created_at":"2021-01-18T14:47:39.557Z","updated_at":"2025-02-25T14:50:25.163Z","phase":"Phase 3","brief_title":"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT03007147 - AALL1631","lead_sponsor":"Children's Oncology Group","biomarkers":" ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R","pipe":" | ","alterations":" BCR-ABL1 fusion • ABL1 fusion","tags":["ABL1 • BCR • PDGFRA • PDGFRB • IKZF1 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • ABL1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • dexamethasone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexrazoxane • levoleucovorin calcium • prednisolone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 475","initiation":"Initiation: 08/08/2017","start_date":" 08/08/2017","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2025-02-13"},{"id":"b88cc8bc-838d-43e3-8862-07db1c3a612f","acronym":"SWOG-S1318","url":"https://clinicaltrials.gov/study/NCT02143414","created_at":"2021-01-18T09:57:21.812Z","updated_at":"2025-02-25T16:36:22.860Z","phase":"Phase 2","brief_title":"Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT02143414 - SWOG-S1318","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R","pipe":" | ","alterations":" ABL2 fusion","tags":["ABL1 • BCR • PDGFRA • FGFR • PDGFRB • CD4 • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ABL2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Blincyto (blinatumomab) • methotrexate • vincristine • prednisone • mercaptopurine delayed release (DR6MP) • mercaptopurine • Xatmep (methotrexate oral solution)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 06/30/2015","start_date":" 06/30/2015","primary_txt":" Primary completion: 06/01/2022","primary_completion_date":" 06/01/2022","study_txt":" Completion: 10/23/2025","study_completion_date":" 10/23/2025","last_update_posted":"2025-02-06"},{"id":"8f093304-44ac-4ac6-aa1f-9424e042581c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02494882","created_at":"2021-01-18T12:01:48.985Z","updated_at":"2025-02-25T15:42:29.508Z","phase":"Phase 1","brief_title":"Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older","source_id_and_acronym":"NCT02494882","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP","pipe":" | ","alterations":" BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R","tags":["ABL1 • BCR • PDGFRB • CRLF2 • JAK3 • CSF1R • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 E255K • BCR-ABL1 V299L • BCR-ABL1 F317L • ABL1 T315I • BCR-ABL1 L248V • BCR-ABL1 Q252H • BCR-ABL1 F317V • JAK3 mutation • ABL1 E255K • BCR-ABL1 F317C • BCR-ABL1 T315A • ABL1 F317L • BCR-ABL1 L248R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib • Jakafi (ruxolitinib) • dexamethasone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/29/2015","start_date":" 06/29/2015","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-07-29"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"6d4a3258-2b1b-4296-b36c-80ae974d4943","acronym":"","url":"https://clinicaltrials.gov/study/NCT04501614","created_at":"2021-01-18T21:33:45.485Z","updated_at":"2024-07-02T16:35:16.674Z","phase":"Phase 1/2","brief_title":"A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT04501614","lead_sponsor":"Takeda","biomarkers":" ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4","pipe":" | ","alterations":" BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation","tags":["ABL1 • BCR • IGH • PDGFRB • CSF1R • PIAS4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCR-ABL1 fusion • BCR-ABL1 T315I • ABL1 T315I • BCR-ABL1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • Iclusig (ponatinib) • cyclophosphamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/24/2021","start_date":" 02/24/2021","primary_txt":" Primary completion: 12/19/2024","primary_completion_date":" 12/19/2024","study_txt":" Completion: 01/04/2027","study_completion_date":" 01/04/2027","last_update_posted":"2024-03-04"},{"id":"04c90704-8700-4d3e-a27e-a296905600ec","acronym":"RELAX","url":"https://clinicaltrials.gov/study/NCT04330820","created_at":"2024-02-28T20:31:08.640Z","updated_at":"2024-07-02T16:35:17.236Z","phase":"Phase 1/2","brief_title":"Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)","source_id_and_acronym":"NCT04330820 - RELAX","lead_sponsor":"Technische Universität Dresden","biomarkers":" TP53 • JAK2 • RUNX1 • PDGFRB • WT1","pipe":"","alterations":" ","tags":["TP53 • JAK2 • RUNX1 • PDGFRB • WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • mitoxantrone"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/06/2020","start_date":" 04/06/2020","primary_txt":" Primary completion: 10/11/2023","primary_completion_date":" 10/11/2023","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-02-28"},{"id":"1c457901-9a43-4dcc-9740-e44b1b37ea65","acronym":"NCI-2018-03465","url":"https://clinicaltrials.gov/study/NCT03862157","created_at":"2021-01-18T19:03:08.762Z","updated_at":"2024-07-02T16:35:23.829Z","phase":"Phase 1/2","brief_title":"Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","source_id_and_acronym":"NCT03862157 - NCI-2018-03465","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA","pipe":" | ","alterations":" NPM1 mutation • CEBPA mutation • PDGFRA rearrangement","tags":["ABL1 • BCR • NPM1 • PDGFRA • PDGFRB • CEBPA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NPM1 mutation • CEBPA mutation • PDGFRA rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • pevonedistat (MLN4924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/27/2019","start_date":" 02/27/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-01-10"},{"id":"34bea2f2-8a1e-4060-9d83-36b2c4268cbc","acronym":"Study 0314","url":"https://clinicaltrials.gov/study/NCT02268253","created_at":"2021-01-18T10:39:50.644Z","updated_at":"2024-07-02T16:35:52.835Z","phase":"Phase 2","brief_title":"Tagraxofusp (SL-401) in Patients With CMML or MF","source_id_and_acronym":"NCT02268253 - Study 0314","lead_sponsor":"Stemline Therapeutics, Inc.","biomarkers":" PDGFRA • JAK2 • PDGFRB • PCM1","pipe":" | ","alterations":" FGFR1 rearrangement","tags":["PDGFRA • JAK2 • PDGFRB • PCM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elzonris (tagraxofusp-erzs)"],"overall_status":"Completed","enrollment":" Enrollment 82","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 03/07/2023","primary_completion_date":" 03/07/2023","study_txt":" Completion: 03/07/2023","study_completion_date":" 03/07/2023","last_update_posted":"2023-03-21"},{"id":"bbe59d28-d934-4e00-a784-01daf74e8e90","acronym":"","url":"https://clinicaltrials.gov/study/NCT05576181","created_at":"2022-10-12T13:56:47.128Z","updated_at":"2024-07-02T16:36:02.594Z","phase":"Phase 1","brief_title":"Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT05576181","lead_sponsor":"Fundamenta Therapeutics, Ltd.","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IKZF1 • JAK1 • CD22 • IL7R • TCF3 • SH2B3","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IKZF1 • JAK1 • CD22 • IL7R • TCF3 • SH2B3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • etoposide IV • ThisCART19A"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 10/15/2022","start_date":" 10/15/2022","primary_txt":" Primary completion: 01/22/2025","primary_completion_date":" 01/22/2025","study_txt":" Completion: 07/22/2025","study_completion_date":" 07/22/2025","last_update_posted":"2022-10-12"},{"id":"fbe744f1-4127-4b91-9548-593e8806c892","acronym":"FT400-004","url":"https://clinicaltrials.gov/study/NCT05350787","created_at":"2022-04-28T17:56:11.330Z","updated_at":"2024-07-02T16:36:11.294Z","phase":"Phase 1","brief_title":"Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL","source_id_and_acronym":"NCT05350787 - FT400-004","lead_sponsor":"Zhejiang University","biomarkers":" ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IFNG • IL6 • IKZF1 • TNFA • JAK1 • IL2 • IL7R • IL10 • TCF3 • TGFB1 • IL17A • SH2B3 • IL1B","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • PDGFRA • FGFR • JAK2 • PDGFRB • IFNG • IL6 • IKZF1 • TNFA • JAK1 • IL2 • IL7R • IL10 • TCF3 • TGFB1 • IL17A • SH2B3 • IL1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2022-04-28"},{"id":"13a6378f-892e-4f0d-8c8d-47b7eaa35728","acronym":"ALaCART","url":"https://clinicaltrials.gov/study/NCT05038696","created_at":"2021-09-09T13:53:04.247Z","updated_at":"2024-07-02T16:36:24.664Z","phase":"Phase 1","brief_title":"ALaCART-B: Acute Leukemia and Chimeric Antigen Receptor-T Cell Therapy for B-lymphoblastic Leukemia.","source_id_and_acronym":"NCT05038696 - ALaCART","lead_sponsor":"National University Hospital, Singapore","biomarkers":" ABL1 • BCR • CD19 • PDGFRB • TCF3","pipe":" | ","alterations":" CD19 expression","tags":["ABL1 • BCR • CD19 • PDGFRB • TCF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/28/2021","start_date":" 04/28/2021","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2021-09-09"},{"id":"5be61f83-2017-482b-b975-53687f1a8509","acronym":"","url":"https://clinicaltrials.gov/study/NCT02303899","created_at":"2021-01-18T10:53:45.455Z","updated_at":"2024-07-02T16:36:35.735Z","phase":"Phase 2","brief_title":"Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma","source_id_and_acronym":"NCT02303899","lead_sponsor":"Istituto Clinico Humanitas","biomarkers":" KIT • PDGFRB","pipe":"","alterations":" ","tags":["KIT • PDGFRB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • imatinib • pemetrexed"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2021-01-22"},{"id":"560d1c05-5369-4204-a6a9-9952268adb6a","acronym":"SIGNATURE","url":"https://clinicaltrials.gov/study/NCT01831726","created_at":"2021-01-18T08:08:43.044Z","updated_at":"2024-07-02T16:37:24.306Z","phase":"Phase 2","brief_title":"Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib","source_id_and_acronym":"NCT01831726 - SIGNATURE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FLT3 • NTRK1 • KDR • PDGFRB • CSF1R","pipe":"","alterations":" ","tags":["FLT3 • NTRK1 • KDR • PDGFRB • CSF1R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dovitinib (TKI258)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 12/01/2015","primary_completion_date":" 12/01/2015","study_txt":" Completion: 12/01/2015","study_completion_date":" 12/01/2015","last_update_posted":"2017-03-20"},{"id":"ee2359d4-314f-402b-b016-07b5131d6e97","acronym":"","url":"https://clinicaltrials.gov/study/NCT00150072","created_at":"2021-01-18T23:14:50.146Z","updated_at":"2024-07-02T16:37:25.097Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Imatinib in Chordoma","source_id_and_acronym":"NCT00150072","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PDGFRB • PDGFB","pipe":"","alterations":" ","tags":["PDGFRB • PDGFB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 04/01/2008","primary_completion_date":" 04/01/2008","study_txt":" Completion: 04/01/2008","study_completion_date":" 04/01/2008","last_update_posted":"2017-02-23"}]